Supplementary Material for: Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention Davlouros P. Xanthopoulou I. Goudevenos J. Hamilos M. Vavuranakis E. Sitafidis G. Kanakakis I. Deftereos S. Alexopoulos D. 10.6084/m9.figshare.5249209.v1 https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Contemporary_Antiplatelet_Treatment_in_Acute_Coronary_Syndrome_Patients_with_Impaired_Renal_Function_Undergoing_Percutaneous_Coronary_Intervention/5249209 <p><b><i>Objectives:</i></b> To assess the clinical impact of impaired renal function (IRF), in “real-world” acute coronary syndrome (ACS) patients, receiving clopidogrel, prasugrel, or ticagrelor. <b><i>Methods:</i></b> This was a prospective, observational, multicenter, cohort study of ACS patients undergoing percutaneous coronary interventions (PCI) with IRF (creatinine clearance <60 mL/min by Cockroft-Gault equation), who were recruited into the Greek Antiplatelet Registry (GRAPE). Patients were followed-up until 1 year for major adverse cardiovascular events (MACE; a composite of death, nonfatal myocardial infarction, urgent revascularization, and stroke) and BARC (Bleeding Academic Research Consortium) bleeding. <b><i>Results:</i></b> Out of 2,047 registered patients, there were 344 (16.8%) with IRF. At the 1-year follow-up, MACE occurred in 18.6 and 6.2% of those patients with and without IRF, respectively: adjusted hazard ratio (HR) = 2.13 (95% confidence interval, CI 1.16-3.91), <i>p</i> = 0.02. IRF patients were also at higher risk of death and BARC type ≥2 and ≥3 bleeding: adjusted HR = 3.55 (95% CI 1.73-7.27), <i>p</i> = 0.001; HR = 2.75 (95% CI 1.13-6.68), <i>p</i> = 0.03; and HR = 6.02 (95% CI 2.30-15.77), <i>p</i> < 0.001, respectively. Combined MACE and BARC type ≥2 bleeding occurred in 34.0 and 14.0% of those with and without IRF, respectively: adjusted HR = 2.65 (95% CI 1.36-5.16), <i>p</i> = 0.004. At discharge, clopidogrel was more frequently prescribed in IRF patients (61.0 vs. 33.1%, <i>p</i> < 0.001). <b><i>Conclusions:</i></b> Real-world ACS patients with IRF subjected to PCI demonstrate higher thrombotic and bleeding risks than patients with normal renal function.</p> 2017-07-27 12:14:23 Cohort study Percutaneous coronary intervention Impaired renal function Ticagrelor Prasugrel Clopidogrel